IO Biotech, Inc. (IOBT)
NASDAQ: IOBT · Real-Time Price · USD
0.6967
+0.0186 (2.74%)
At close: Dec 5, 2025, 4:00 PM EST
0.7138
+0.0171 (2.45%)
After-hours: Dec 5, 2025, 7:59 PM EST
IO Biotech Stock Forecast
Stock Price Forecast
According to 2 professional analysts, the 12-month price target for IO Biotech stock ranges from a low of $3.00 to a high of $4.00. The average analyst price target of $3.50 forecasts a 402.37% increase in the stock price over the next year.
Price Target: $3.50 (+402.37%)
Analyst Consensus: Buy
* Price targets were last updated on Oct 22, 2025.
Analyst Ratings
The average analyst rating for IO Biotech stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 0 | 0 | 0 | 0 |
| Buy | 2 | 2 | 1 | 2 | 2 | 2 |
| Hold | 0 | 0 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $10 → $3 | Buy | Maintains | $10 → $3 | +330.60% | Oct 22, 2025 |
| TD Cowen | TD Cowen | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Sep 30, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Sep 29, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $6 → $4 | Buy | Maintains | $6 → $4 | +474.14% | Aug 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +1,622.41% | Apr 1, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
11.02M
EPS This Year
-1.19
from -1.45
EPS Next Year
-0.45
from -1.19
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | 31.2M | ||||
| Avg | n/a | 11.0M | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.00 | -0.19 | |
| Avg | -1.19 | -0.45 | |
| Low | -1.27 | -0.65 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.